Compile Data Set for Download or QSAR
maximum 50k data
Found 773 with Last Name = 'novak' and Initial = 'a'
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263238(5-amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1h-pyrazol...)
Affinity DataIC50:  0.330nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263258(3-amino-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]...)
Affinity DataIC50:  0.670nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263231(3-cyano-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]...)
Affinity DataIC50:  0.740nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263235(3-(3,5-dimethyl-isoxazol-4-yl)-1-[4-(4-methyl-pyra...)
Affinity DataIC50:  0.890nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263298(1-(4-pyrazol-1-ylmethyl-benzyl)-3-trifluoromethyl-...)
Affinity DataIC50:  0.920nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCTP synthase 2(Rattus norvegicus)TBA
LigandPNGBDBM50609673(CHEMBL5267968)
Affinity DataIC50:  1nMAssay Description:Inhibition of rat CTPS2 preincubated for 10 mins followed by substrate addition and measured after 30 to 60 mins by RFMS assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156158(CHEMBL3781244)
Affinity DataIC50:  1nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263229(3-hydroxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)...)
Affinity DataIC50:  1.17nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263259(3-methoxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)...)
Affinity DataIC50:  1.27nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263261(3-difluoromethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl...)
Affinity DataIC50:  1.68nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263221(3-methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl...)
Affinity DataIC50:  1.89nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM206344(US9260410, 2)
Affinity DataIC50:  2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156160(CHEMBL3780667)
Affinity DataIC50:  2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156162(CHEMBL3781245)
Affinity DataIC50:  2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263248(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-pyra...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263342(1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...)
Affinity DataIC50:  2.14nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263224(3-isopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-ben...)
Affinity DataIC50:  2.14nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263253(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifl...)
Affinity DataIC50:  2.16nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263301(1-(6-pyrazol-1-ylmethyl-pyridin-3-ylmethyl)-3-trif...)
Affinity DataIC50:  2.29nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263215(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-imid...)
Affinity DataIC50:  2.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263215(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-imid...)
Affinity DataIC50:  2.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263223(3-cyclopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-b...)
Affinity DataIC50:  2.58nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263250(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-[1,2...)
Affinity DataIC50:  2.80nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156129(CHEMBL3782036)
Affinity DataIC50:  3nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263252(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-pheny...)
Affinity DataIC50:  3.68nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263213(1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...)
Affinity DataIC50:  3.72nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359614(N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methyl...)
Affinity DataIC50:  3.86nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359614(N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methyl...)
Affinity DataIC50:  3.86nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263263(2,5-dimethyl-1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-be...)
Affinity DataIC50:  3.90nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263317(3-amino-1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1...)
Affinity DataIC50:  4.15nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263228(3-cyclobutyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-be...)
Affinity DataIC50:  4.62nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263262(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-thiop...)
Affinity DataIC50:  4.85nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM142597(US8933228, Ref 1)
Affinity DataIC50:  5nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM261344(1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...)
Affinity DataIC50:  5.38nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263281(1-[6-((s)-3-methyl-pyrrolidin-1-yl)-pyridin-3-ylme...)
Affinity DataIC50:  5.84nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156133(CHEMBL3782009)
Affinity DataIC50:  6nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156135(CHEMBL3781413)
Affinity DataIC50:  6nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156144(CHEMBL3781687)
Affinity DataIC50:  6nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263236(1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-morph...)
Affinity DataIC50:  6.46nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263240(3-cyclopropyl-1-(5-methoxy-6-pyrrolidin-1-yl-pyrid...)
Affinity DataIC50:  7.31nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535979(N-{[4-(Aminomethyl)-2,6-dimethylphenyl]methyl}-5-(...)
Affinity DataIC50:  7.47nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359712(N-{[4-(Aminomethyl)-2,6-dimethylphenyl]methyl}-5-(...)
Affinity DataIC50:  7.47nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156163(CHEMBL3780832)
Affinity DataIC50:  8nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156128(CHEMBL3780488)
Affinity DataIC50:  8nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156157(CHEMBL3781473)
Affinity DataIC50:  9nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263282(1-[6-((s)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-ylme...)
Affinity DataIC50:  9.61nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263239(1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-trifluo...)
Affinity DataIC50:  9.66nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM263286(1-(2-pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-3-trifl...)
Affinity DataIC50:  10.4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156126(CHEMBL3780111)
Affinity DataIC50:  11nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 14(Homo sapiens (Human))
Sygnature Discovery

Curated by ChEMBL
LigandPNGBDBM50156127(CHEMBL3781430)
Affinity DataIC50:  11nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 773 total ) | Next | Last >>
Jump to: